FormBlends Video Library · FormBlends network
Watch the best GLP-1 explainers, with the mistakes flagged for you.
Twenty-seven videos from universities, health systems and medical educators, each with a written fact-check: what it gets right, what it leaves out.
- 27
- videos, each with a written fact-check beside it
- Each embedded with a written fact-check beside it, sourced to labels and trials.
- 6
- playlists in watch order
- Playlists in watch order, from what GLP-1s are to what the outcome trials showed.
- 17,604
- people in SELECT, not the 177,000 one auto-caption says
- The real number of people in the SELECT trial. One auto-caption says 177,000.
Start here
Three ways in, depending on what you need right now
- 01Video player with fact-checkClick-to-load YouTube embed for the video on this page, with channel attribution and the rest of its playlist.
- 02How we choose videosVideos come only from universities, hospitals, medical groups, government agencies or named doctors who teach.
- 03Browse playlists6 pages, most recently updated September 4, 2026
Interactive
Calculators
Each runs in your browser, shows its formula, and prints a dated assumptions note. Nothing you type leaves the page.
CalculatorVideo player with fact-check
Click-to-load YouTube embed for the video on this page, with channel attribution and the rest of its playlist.
CalculatorPlaylist player
One playlist in watch order: an embed for each video with what it gets right and what it leaves out beside it.
Reading
Start with these
Each page opens with a plain-English summary, a figure drawn from the data, the numbers that matter, and what it means if you're considering treatment.
Editorial
How we choose videos
You'll get: Videos come only from universities, hospitals, medical groups, government agencies or named doctors who teach.
The inclusion rules, the verification step, what we never embed, how the fact-checks are written and sourced, and how a video leaves the library.
Playlists
Playlist: How GLP-1s work
You'll get: Five videos explain how GLP-1 drugs copy a gut hormone that acts on appetite, digestion and blood sugar.
Five videos on mechanism, from a 90-second hospital explainer to a 38-minute academic podcast, in the order that builds understanding. Each has a written fact-check with the label and trial sources.
Playlists
Playlist: Side effects and safety
You'll get: Five videos cover stomach side effects, surgery risks and compounded drugs. Each gives the trial rates.
Five videos: an emergency physician's case mix, an obesity physician on what to do about each GI effect, the anaesthesia question from a patient-safety foundation, a medical society podcast on compounded products, and a dietitian's hour with the trial percentages.
Videos
Fact-check: NEJM's two-minute summary of the SELECT trial
You'll get: The journal's own summary of a trial of semaglutide in people with heart disease and obesity but no diabetes.
The journal's own two-minute summary of the SELECT heart trial. Every figure is from the paper; we add what it leaves out and who the result applies to.
Videos
Fact-check: the Veterans Health Administration's subcutaneous injection demonstration
You'll get: A government health video shows every step of injecting from a vial with a syringe, the format compounded drugs come in.
A government health system's step-by-step vial-and-syringe technique. Correct throughout for what it shows; here is what a person injecting a GLP-1 from a vial must add, especially about concentration and units.
Live updates
What changed since this site was written
Sources checked November 5, 2026, refreshed every six hours.
Newest on PubMed
Papers indexed in the last year matching reviews and guidelines (201 in total).
- Efficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials
J Diabetes Metab Disord · October 31, 2026 · PubMed 42968774
- Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses
Expert Opin Pharmacother · October 29, 2026 · PubMed 42952336
- Interpreting Diabetic Retinal Outcomes After GLP-1 Receptor Agonist and Tirzepatide Initiation: Clinical Evidence and Its Limits
Diabetes Obes Metab · October 27, 2026 · PubMed 42946946
- Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity
Rambam Maimonides Med J · October 26, 2026 · PubMed 42957176
- Pancreatic and Gallbladder Adverse Events Associated with Tirzepatide in Obesity Management: A Scoping Review
Diabetes Metab Syndr Obes · October 23, 2026 · PubMed 42948670
FDA and enforcement tracker
FormBlends research feed, data as of September 4, 2026.
September 1, 2026 · Adverse-event report update
FDA GLP-1 concerns page updated: 990 adverse-event reports for compounded semaglutide and >730 for compounded tirzepatide (as of May 31, 2026); border screening and fake-pharmacy labelsAugust 28, 2026 · Label or price event
FDA approves Mounjaro (tirzepatide) to reduce MACE risk in adults with type 2 diabetes (SURPASS-CVOT)August 27, 2026 · Court decision
Fifth Circuit affirms summary judgment for FDA in both GLP-1 shortage cases (Nos. 25-10600 tirzepatide; 25-10758 semaglutide)August 24, 2026 · FDA warning letter
FDA warning letters to five peptide vendors: Peak Performance Peptides (735127), Royal Peptides (734884), NuScience Peptides (733652), Peptide Partners (735063), TXP Innovations dba Tex Peptides (735067)August 24, 2026 · FDA warning letter
FDA warning letter: TXP Innovations LLC dba Tex Peptides (Unapproved New Drugs/Misbranded)
Compounded price index
Median all-in cash price per 28 days across providers, as of September 3, 2026.
- semaglutide, month 1 at 0.25 mg/week
- $197
- median of 14 providers
- semaglutide, month 4 at 1 mg/week
- $199
- median of 13 providers
- tirzepatide, month 1 at 2.5 mg/week
- $268
- median of 14 providers
- tirzepatide, month 4 at 5 mg/week
- $299
- median of 12 providers
- September 3, 2026: Index, All, baseline 51 rows. First weekly snapshot. Changes against this baseline will be listed here with the date they were observed.
PubMed lists come from NCBI E-utilities and are not reviewed by us before they appear. Feeds are FormBlends Research data (CC BY 4.0); FormBlends sells compounded GLP-1 drugs and appears in the price index under the same rules as every other provider. Compounded drugs are not FDA approved.
Browse
Sections
35 pages across 3 sections, each sourced to a label, a trial or a dated manufacturer page.
Playlists
You'll get: 6 sourced pages, each with a plain-English opener
Five videos on mechanism, from a 90-second hospital explainer to a 38-minute academic podcast, in the order...
Videos
You'll get: 27 sourced pages, each with a plain-English opener
Nick Sterling, MD, PhD ranks what he sees in the emergency department: nausea and vomiting, dehydration and...
Editorial
You'll get: 2 sourced pages, each with a plain-English opener
The inclusion rules, the verification step, what we never embed, how the fact-checks are written and...
Why fact-check a good video
The best explainer channels compress. A ninety-second hospital video on how a GLP-1 works is accurate as far as it goes, but it cannot fit the label's boxed warning, the placebo-subtracted trial number or the difference between a brand pen and a compounded vial. The write-up under each video supplies what the runtime could not, with the DailyMed set id or PubMed id for every number.
How the six playlists fit together
Start with how GLP-1s work, then take the tirzepatide or semaglutide playlist depending on the medication you are asking about. The side effects and safety playlist covers the label warnings and the peri-operative question. Injections and practical use is technique from health systems and a government agency. Obesity science and outcomes is the longer lectures on why weight returns and what the outcome trials measured.
What this site is not
It is not a channel, a video host or a source of medical advice. We do not embed creator TikToks, influencer reviews or product promotions, and a video's presence here is not an endorsement by its channel of FormBlends. Where a fact-check mentions compounded semaglutide or tirzepatide it says what they are: not FDA approved and not interchangeable with brand products.